venous leg ulcers

Interview

Update on the IGuideU Trial: An Interview With Paul Gagne, MD

02/16/2023

Paul Gagne, MD, FACS, RVT

Vascular Care Connecticut, Darien, Connecticut

Paul Gagne, MD, FACS, RVT Vascular C...

At the 2022 VEITH Symposium, Paul Gagne, MD, presented an update on the IGuideU trial, a multi-center, randomized controlled trial to determine if the use of IVUS as an adjunctive imaging modality and as an interventional treatment guide will...

At the 2022 VEITH Symposium,...

02/16/2023

Vascular Disease Management

Empirical Studies

A Prospective Noninterventional Study of Type I Collagen Matrix Plus Polyhexamethylene Biguanide Antimicrobial for the Treatment of Venous Leg Ulcers: A Secondary Analysis

06/01/2022

George J. Koullias, MD

Michael A. Bain, MD

Kerry Thibodeaux, MD

Michael Sabolinski, MD

Analysis of VLUs in the RESPOND registry

Analysis of VLUs in the RESPOND...

06/01/2022

Wound Management & Prevention

A comparative effectiveness research study of a native Type I collagen matrix plus polyhexamethylene biguanide antimicrobial and a cryopreserved cadaveric skin allograft for use in venous leg ulcers – a non-inferiority analysis

OBJECTIVES: Real-world effectiveness was evaluated in a large patient population at 212 US treatment facilities comparing a purified native cross-linked extracellular matrix plus polyhexa...

08/19/2021

Weekly Changes in Wound Parameters Following Treatment with Either Single-Use or Traditional Negative Pressure Wound Therapy: Results of a Randomized Controlled Trial in Patients with Venous Leg Ulcers and Diabetic Foot Ulcers

Introduction: Early intervention with negative pressure wound therapy (NPWT) in hard-to-heal wounds is associated not only with improved outcomes, but also with lower costs of treatment. ...

12/11/2019

Value for Money: Using Bilayered Living Cellular Construct for Treatment of Venous Leg Ulcers

Introduction: Treatment of venous leg ulcers (VLUs) presents a significant economic burden on the U.S. health-care system and payers. The total U.S. annual economic burden of VLUs is equa...

12/02/2019

Using a Novel Cyanoacrylate Skin Protectant to Reduce Periwound Tissue Breakdown with Venous Leg Ulcers Under Compression and with Prolonged Use Offloading Devices

The purpose of this study was to evaluate the effect of applying a novel cyanoacrylate skin protectant to reduce periwound MASD in chronic venous leg ulcers under an extended wear compres...

11/25/2019

A New Multilayer Wound Dressing That Transports Toxic Matrix Metalloproteases (MMPs) from Chronic Wound Fluid Away from the Wound

Objective: The aim of this case series was twofold: 1) To study the absorptive profile of a new multilayer wound dressing (MBF)* designed to spread wound fluid away from the wound; and 2)...

11/04/2019

Effective Treatment of Chronic Venous Leg Ulcers Using Acellular Dermal Matrix

Objectives: Venous leg ulcers (VLUs) lasting more than 12 months are slow to heal. One study calculated that chronic VLUs have a 22% chance of healing compared to an 80% chance for acute ...

10/24/2019

Phase 1 Open-label Preliminary Assessment of a Thin, Flexible Pressure Sensor for Therapeutic Compression Garments Using a Cohort of Healthy Adults

Background: Venous leg ulcers (VLUs) are the most common wounds of the lower extremities (LEs), affecting approximately 600,000 patients at a cost of $2.5-3.5 billion USD annually. L...

08/19/2019

Increased Healing Rates of Venous Leg Ulcers Treated with Native Type I Collagen Matrix Plus Polyhexamethylene Biguanide (PHMB) Antimicrobial in Addition to Standard Practices: Interim Results from the RESPOND Registry

Objective: Bacterial bioburden and biofilm can result in elevated protease activity which has been associated with prolonging the inflammatory phase, and contribute to the chronicity of v...

08/12/2019